Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2-(4-(4-fluoro-benzyl)-piperidin-1-yl)-2-oxo-n-(2-oxo-2,3-dihydro-benzooxazol-6-yl)-acetamide
1. 496054-87-6
2. Rgh-896
3. Radiprodil [inn]
4. 5xgc17zkuf
5. Chembl182066
6. 2-(4-(4-fluorobenzyl)piperidin-1-yl)-2-oxo-n-(2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)acetamide
7. 2-(4-((4-fluorophenyl)methyl)piperidin-1-yl)-2-oxo-n-(2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)acetamide
8. 2-[4-(4-fluoro-benzyl)-piperidin-1-yl]-2-oxo-n-(2-oxo-2,3-dihydro-benzooxazol-6-yl)-acetamide
9. Unii-5xgc17zkuf
10. Radiprodil (rgh-896)
11. Radiprodil [who-dd]
12. Schembl99256
13. Dtxsid80964297
14. Rgh 896
15. Bcp30852
16. Wua05487
17. Bdbm50149684
18. S6644
19. Zinc28363953
20. Db12260
21. 2-[4-(4-fluorobenzyl)piperidin-1-yl]-2-oxo-n-(2-oxo-2,3-dihydrobenzoxazol-6-yl)acetamide
22. Ncgc00386549-01
23. 2-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]-2-oxo-n-(2-oxo-3h-1,3-benzoxazol-6-yl)acetamide
24. 2-{4-[(4-fluorophenyl)methyl]piperidin-1-yl}-n-(2-hydroxy-1,3-benzoxazol-6-yl)-2-oxoacetamide
25. Bs-16896
26. Hy-14777
27. Cs-0003554
28. Rgh-896; Rgh896; Rgh 896
29. N16882
30. Q27263011
31. 1-piperidineacetamide, N-(2,3-dihydro-2-oxo-6-benzoxazolyl)-4-[(4-fluorophenyl)methyl]-alpha-oxo-
32. 2-[4-(4-fluoro-benzyl)-piperidin-1-yl]-2-oxo-n-(2-oxo-2,3-dihydro-benzoxazol-6-yl)-acetamide
33. 2-[4-(4-fluorobenzyl)-piperidin-1-yl]-2-oxo-n-(2-oxo-2,3-dihydro-benzoxazol-6-yl)-acetamide
34. N-(2,3-dihydro-2-oxo-6-benzoxazolyl)-4-[(4-fluorophenyl)methyl]-alpha-oxo-1-piperidineacetamide
| Molecular Weight | 397.4 g/mol |
|---|---|
| Molecular Formula | C21H20FN3O4 |
| XLogP3 | 3 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 3 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 87.7 |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 629 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
Radiprodil is a potent negative allosteric modulator of the NMDA receptor subtype 2B. It is being evaluated for seizures associated with GRIN-related neurodevelopmental disorder with GoF mutations.
Lead Product(s): Radiprodil
Therapeutic Area: Neurology Brand Name: RGH-896
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 06, 2025
Lead Product(s) : Radiprodil
Therapeutic Area : Neurology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GRIN gets EU Orphan Designation for Radiprodil in GRIN Neurodevelopmental Disorder
Details : Radiprodil is a potent negative allosteric modulator of the NMDA receptor subtype 2B. It is being evaluated for seizures associated with GRIN-related neurodevelopmental disorder with GoF mutations.
Product Name : RGH-896
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 06, 2025
Details:
Radiprodil is a potent negative allosteric modulator of the NMDA receptor subtype 2B. It is being evaluated for seizures associated with GRIN-related neurodevelopmental disorder with GoF mutations.
Lead Product(s): Radiprodil
Therapeutic Area: Neurology Brand Name: RGH-896
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 01, 2025
Lead Product(s) : Radiprodil
Therapeutic Area : Neurology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GRIN Therapeutics Gets PRIME Designation From EMA for Radiprodil
Details : Radiprodil is a potent negative allosteric modulator of the NMDA receptor subtype 2B. It is being evaluated for seizures associated with GRIN-related neurodevelopmental disorder with GoF mutations.
Product Name : RGH-896
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 01, 2025
Details:
Radiprodil is a potent negative allosteric modulator of the NMDA receptor subtype 2B. It is being evaluated for seizures associated with GRIN-related neurodevelopmental disorder with GoF mutations.
Lead Product(s): Radiprodil
Therapeutic Area: Neurology Brand Name: RGH-896
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 17, 2025
Lead Product(s) : Radiprodil
Therapeutic Area : Neurology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Grin Therapeutics Gets FDA Orphan Drug Tag for Radiprodil in Grin-Related Disorder
Details : Radiprodil is a potent negative allosteric modulator of the NMDA receptor subtype 2B. It is being evaluated for seizures associated with GRIN-related neurodevelopmental disorder with GoF mutations.
Product Name : RGH-896
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 17, 2025
Details:
Radiprodil is a potent negative allosteric modulator of the NMDA receptor subtype 2B. It is being evaluated for seizures associated with GRIN-related neurodevelopmental disorder with GoF mutations.
Lead Product(s): Radiprodil
Therapeutic Area: Neurology Brand Name: RGH-896
Study Phase: Phase I/ Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 25, 2025
Lead Product(s) : Radiprodil
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GRIN Therapeutics Receives FDA Breakthrough Therapy Designation for Radiprodil
Details : Radiprodil is a potent negative allosteric modulator of the NMDA receptor subtype 2B. It is being evaluated for seizures associated with GRIN-related neurodevelopmental disorder with GoF mutations.
Product Name : RGH-896
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 25, 2025
Details:
RGH-896 (radiprodil) is an investigational, selective and potent negative allosteric modulator of the N-methyl-D-aspartate receptor subtype 2B (NR2B or GluN2B).
Lead Product(s): Radiprodil
Therapeutic Area: Neurology Brand Name: RGH-896
Study Phase: Phase I/ Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 09, 2024
Lead Product(s) : Radiprodil
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GRIN Therapeutics Reports Positive Data from Honeycomb Trial of Radiprodil
Details : RGH-896 (radiprodil) is an investigational, selective and potent negative allosteric modulator of the N-methyl-D-aspartate receptor subtype 2B (NR2B or GluN2B).
Product Name : RGH-896
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 09, 2024
Details:
Radiprodil is a potent negative allosteric modulator of the NMDA receptor subtype 2B. It is being evaluated for the treatment of Tuberous Sclerosis Complex and Focal Cortical Dysplasia Type II.
Lead Product(s): Radiprodil
Therapeutic Area: Rare Diseases and Disorders Brand Name: RGH-896
Study Phase: Phase I/ Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 10, 2024
Lead Product(s) : Radiprodil
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GRIN Initiates Astroscape Trial of Radiprodil For Tuberous Sclerosis Complex
Details : Radiprodil is a potent negative allosteric modulator of the NMDA receptor subtype 2B. It is being evaluated for the treatment of Tuberous Sclerosis Complex and Focal Cortical Dysplasia Type II.
Product Name : RGH-896
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 10, 2024
Details:
Radiprodil is a selective NAM of the Nmethyl-D-aspartate receptor subtype 2B. It inhibits NMDA glutamate currents when tested using receptors containing NR2B subunits coded by GoF mutations in the GRIN2B and GRIN2A genes, which are known to cause GRIN-related disorders.
Lead Product(s): Radiprodil
Therapeutic Area: Genetic Disease Brand Name: RGH-896
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 23, 2023
Lead Product(s) : Radiprodil
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Radiprodil is a selective NAM of the Nmethyl-D-aspartate receptor subtype 2B. It inhibits NMDA glutamate currents when tested using receptors containing NR2B subunits coded by GoF mutations in the GRIN2B and GRIN2A genes, which are known to cause GRIN-re...
Product Name : RGH-896
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 23, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
26
PharmaCompass offers a list of Radiprodil API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Radiprodil manufacturer or Radiprodil supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Radiprodil manufacturer or Radiprodil supplier.
PharmaCompass also assists you with knowing the Radiprodil API Price utilized in the formulation of products. Radiprodil API Price is not always fixed or binding as the Radiprodil Price is obtained through a variety of data sources. The Radiprodil Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Radiprodil manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Radiprodil, including repackagers and relabelers. The FDA regulates Radiprodil manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Radiprodil API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Radiprodil supplier is an individual or a company that provides Radiprodil active pharmaceutical ingredient (API) or Radiprodil finished formulations upon request. The Radiprodil suppliers may include Radiprodil API manufacturers, exporters, distributors and traders.
Radiprodil Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Radiprodil GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Radiprodil GMP manufacturer or Radiprodil GMP API supplier for your needs.
A Radiprodil CoA (Certificate of Analysis) is a formal document that attests to Radiprodil's compliance with Radiprodil specifications and serves as a tool for batch-level quality control.
Radiprodil CoA mostly includes findings from lab analyses of a specific batch. For each Radiprodil CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Radiprodil may be tested according to a variety of international standards, such as European Pharmacopoeia (Radiprodil EP), Radiprodil JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Radiprodil USP).
